Episode Details
Back to Episodes
Cutting-Edge Concepts in HIV Care: PrEP
Episode 214
Published 3 years, 4 months ago
Description
In this episode, Paul E. Sax, MD, discusses the latest recommendations and options for HIV pre-exposure prophylaxis (PrEP), including:
- CDC PrEP guideline 2021 updates for oral PrEP
- The ANRS IPERGAY study: on-demand oral emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) PrEP in men who have sex with men who are at high risk for HIV infection
- A review of the HPTN 083 and 084 studies: efficacy and safety of long-acting (LA) injectable cabotegravir (CAB) vs daily oral FTC/TDF for PrEP
- 1-year follow-up after unblinding for HPTN 083 and 084
- LA CAB for PrEP: monitoring and safety
- Stopping LA CAB for PrEP
Presenter:
Paul E. Sax, MD
Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Link to full program:
https://bit.ly/3VIsDTg
Follow along with the slides at:
https://bit.ly/3Gh9AKG
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.